| scholarly article | Q13442814 |
| P50 | author | Rahul M. Kohli | Q55189769 |
| P2093 | author name string | Trevor Selwood | |
| Paul M Keller | |||
| Amy Quinn | |||
| Katherine L Widdowson | |||
| Jessica Schneck | |||
| Andrew J Pope | |||
| Charlie Y Mo | |||
| Matthew J Culyba | |||
| Zachary M Hostetler | |||
| Anthony J Jurewicz | |||
| Jeffrey M Kubiak | |||
| P2860 | cites work | SOS response induces persistence to fluoroquinolones in Escherichia coli | Q21144990 |
| Inhibition of mutation and combating the evolution of antibiotic resistance | Q21146100 | ||
| Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection | Q22122301 | ||
| Autodigestion of lexA and phage lambda repressors | Q24597460 | ||
| Sublethal antibiotic treatment leads to multidrug resistance via radical-induced mutagenesis | Q24625342 | ||
| Quinolone Resistance Reversion by Targeting the SOS Response. | Q42264036 | ||
| Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening | Q42763386 | ||
| Suramin is a potent and selective inhibitor of Mycobacterium tuberculosis RecA protein and the SOS response: RecA as a potential target for antibacterial drug discovery. | Q43633453 | ||
| New biarsenical ligands and tetracysteine motifs for protein labeling in vitro and in vivo: synthesis and biological applications | Q44001816 | ||
| Intramolecular cleavage of LexA and phage lambda repressors: dependence of kinetics on repressor concentration, pH, temperature, and solvent | Q44913815 | ||
| In vitro selection of preferred DNA pairing sequences by the Escherichia coli RecA protein. | Q45933165 | ||
| Lessons from 50 years of SOS DNA-damage-induced mutagenesis. | Q46014624 | ||
| RecA Inhibitors Potentiate Antibiotic Activity and Block Evolution of Antibiotic Resistance. | Q50868599 | ||
| University-industry partnership. | Q53495128 | ||
| Effect of recA inactivation on mutagenesis of Escherichia coli exposed to sublethal concentrations of antimicrobials. | Q54372713 | ||
| The Ecstasy and Agony of Assay Interference Compounds | Q60502259 | ||
| Prospects for productivity | Q80070266 | ||
| Conformationally selective binding of nucleotide analogues to Escherichia coli RecA: a ligand-based analysis of the RecA ATP binding site | Q83052942 | ||
| Partnering with the professor | Q87422390 | ||
| Directed molecular screening for RecA ATPase inhibitors | Q24684082 | ||
| The discovery of a novel antibiotic for the treatment of Clostridium difficile infections: a story of an effective academic–industrial partnership | Q26767471 | ||
| A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics | Q26783545 | ||
| Click chemistry in peptide-based drug design | Q26853053 | ||
| Crystal structure of LexA: a conformational switch for regulation of self-cleavage | Q27634783 | ||
| Structure of the LexA–DNA complex and implications for SOS box measurement | Q27664039 | ||
| Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis | Q27681412 | ||
| SOS Repair Hypothesis: Phenomenology of an Inducible DNA Repair Which is Accompanied by Mutagenesis | Q28141658 | ||
| Trypanosoma brucei glycogen synthase kinase-3, a target for anti-trypanosomal drug development: a public-private partnership to identify novel leads | Q28477646 | ||
| The SOS response controls integron recombination. | Q29346620 | ||
| Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles | Q30145662 | ||
| Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli | Q30479751 | ||
| A genetic screen for isolating "lariat" Peptide inhibitors of protein function | Q30921487 | ||
| A comprehensive library of fluorescent transcriptional reporters for Escherichia coli | Q33251466 | ||
| SOS involvement in stress-inducible biofilm formation | Q33625735 | ||
| Novel Inhibitors of E. coli RecA ATPase Activity | Q33637395 | ||
| How antibiotics kill bacteria: from targets to networks | Q33958766 | ||
| Emerging principles in protease-based drug discovery | Q34282102 | ||
| The bacterial LexA transcriptional repressor. | Q34813362 | ||
| Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis | Q35126182 | ||
| Targets for Combating the Evolution of Acquired Antibiotic Resistance | Q35754447 | ||
| High-throughput screening for RecA inhibitors using a transcreener adenosine 5'-O-diphosphate assay | Q36029187 | ||
| A complementary pair of rapid molecular screening assays for RecA activities | Q36091838 | ||
| Controlling mutation: intervening in evolution as a therapeutic strategy | Q36961674 | ||
| SOS regulation of qnrB expression | Q37072051 | ||
| Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy | Q37114251 | ||
| Systematically Altering Bacterial SOS Activity under Stress Reveals Therapeutic Strategies for Potentiating Antibiotics | Q37166834 | ||
| The SOS response promotes qnrB quinolone-resistance determinant expression | Q37304655 | ||
| Drug discovery: new models for industry-academic partnerships | Q37320886 | ||
| Reaction of LexA repressor with diisopropyl fluorophosphate. A test of the serine protease model. | Q38339756 | ||
| SOS response in bacteria: Inhibitory activity of lichen secondary metabolites against Escherichia coli RecA protein | Q38780295 | ||
| Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance | Q39197564 | ||
| Specificity determinants for autoproteolysis of LexA, a key regulator of bacterial SOS mutagenesis. | Q39867010 | ||
| Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial | Q40962449 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | SOS response | Q143584 |
| antivirulent agent | Q25101109 | ||
| P304 | page(s) | 349-359 | |
| P577 | publication date | 2018-01-08 | |
| P1433 | published in | ACS Infectious Diseases | Q24067932 |
| P1476 | title | Inhibitors of LexA Autoproteolysis and the Bacterial SOS Response Discovered by an Academic-Industry Partnership | |
| P478 | volume | 4 |
| Q60949764 | Advancement of the 5-Amino-1-(Carbamoylmethyl)-1H-1,2,3-Triazole-4-Carboxamide Scaffold to Disarm the Bacterial SOS Response |
| Q90571043 | Lytic gene expression in the temperate bacteriophage GIL01 is activated by a phage-encoded LexA homologue |
| Q90192897 | Multitarget Approaches against Multiresistant Superbugs |
| Q89782500 | Targeting the Class A Carbapenemase GES-5 via Virtual Screening |
Search more.